Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kymriah: England Becomes First In Europe To Say Yes To CAR-T

Executive Summary

A new deal between Novartis and England’s National Health Service is one of the fastest funding approvals in the 70-year history of the NHS.

You may also be interested in...



Early Engagement On Outcomes-Based Deals Helps Unlock EU Access To Kymriah

Novartis has managed to temporarily overcome payer reservations about the real-world value of Kymriah by engaging early with payers and heath technology assessment bodies and by developing tailored outcomes-based deals for key European markets. Approaching each payer with a responsible attitude has helped too.

NICE Head Sir Andrew Dillon To Stand Down

Sir Andrew Dillon is leaving his role as CEO of England’s health technology assessment body after 20 years.

Sir Andrew Dillon Standing Down As Head Of England’s NICE After 20 Years

Sir Andrew Dillon is stepping down from what has been described as one of the most challenging and potentially controversial roles in British public life.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS123808

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel